Research Article
Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis
Table 5
The baseline characteristics according to ICPI groups in the chemotherapy cohort.
| | All patients | Low-risk ICPI | Moderately high-risk ICPI | value | | n = 84 | n = 48 | n = 36 |
| | Sex | | | | 0.547 | | Male | 65 (77.4) | 36 (75.5) | 29 (80.6) | |
| | Age (year) | | | | 0.842 | | ≥65 | 29 (34.5) | 17 (35) | 12 (33) | |
| | Smoking status | | | | 0.500 | | Nonsmoker | 32 (38.1) | 20 (41.7) | 12 (33.3) | | | Smoker | 52 (61.9) | 28 (58.3) | 24 (66.7) | |
| | Histology | | | | 0.236 | | Adenocarcinoma | 47 (56.0) | 25 (52.1) | 22 (61.1) | | | Squamous | 33 (39.3) | 19 (39.6) | 14 (38.9) | | | NSCLC-others | 4 (4.8) | 4 (4.8) | 0 (0) | |
| | KRAS alteration status | | | | 0.588 | | KRAS wild-type | 53 (63.1) | 28 (58.3) | 25 (69.4) | | | KRAS-mutant | 4 (4.8) | 3 (6.3) | 1 (2.8) | | | NA | 27 (32.1) | 17 (35.4) | 10 (27.8) | |
| | PD-L1 status | | | | | | Negative | | | | | | Positive | | | | | | NA | | | | |
| | PS (ECOG) | | | | | | 0-1 | 84 (100) | 48 (100) | 36 (100) | | | ≥2 | 0 | 0 | 0 | |
| | Stage | | | | 0.037 | | I-II | 1 (1.2) | 0 (0) | 1 (2.8) | | | IIIA | 5 (6.0) | 5 (10.4) | 0 (0) | | | IIIB–IV | 78 (92.9) | 43 (89.6) | 35 (97) | |
| | Metastatic sites number | | | | 0.042 | | <2 | 32 (38.1) | 23 (47.9) | 9 (25.0) | | | ≥ 2 | 52 (61.9) | 25 (52.1) | 27 (75) | |
| | Metastatic sites | | | | | | Live | 2 (2.4) | 1 (2.1) | 1 (2.8) | 0.836 | | Bone | 17 (20.2) | 10 (20.8) | 7 (19.4) | 0.875 | | Brain | 12 (14.3) | 5 (10.4) | 7 (19.4) | 0.242 | | WBC (×109/L) | 7.41 ± 2.19 | 7.05 ± 1.96 | 7.87 ± 2.42 | 0.091 | | ANC (×109/L) | 5.19 ± 1.91 | 4.62 ± 1.57 | 5.95 ± 2.07 | 0.001 | | ALC (×109/L) | 1.44 ± 0.48 | 1.68 ± 0.42 | 1.13 ± 0.36 | <0.001 | | MON (×109/L) | 0.48 (0.37–0.61) | 0.47 (0.37–0.57) | 0.50 (0.40–0.67) | 0.183 | | RDW (%) | 13.2 (12.7–13.8) | 13.3 (12.7–14.0) | 13.1 (12.6–13.78) | 0.861 | | PLT (×109/L) | 235 (183–297) | 230 (173–276) | 259 (190–361) | 0.054 | | ALB (g/L) | 38.38 ± 4.87 | 40.71 ± 3.62 | 35.28 ± 4.62 | <0.001 | | PLR | 171.6 (119.1–231.4) | 145.4 (108.4–180.0) | 237 (183.1–338.9) | <0.001 | | dNLR | 2.33 (1.77–3.06) | 1.95 (1.56–2.35) | 3.13 (2.39–3.97) | <0.001 |
| | Disease response | | | | 0.137 | | CR | 0 | 0 | 0 | | | PR | 70 (83.3) | 37 (77.1) | 33 (91.7) | | | SD | 14 (16.7) | 11 (22.9) | 3 (8.3) | | | PD | 0 | 0 | 0 | | | NA | | | | |
| | Response rates | | | | 0.139 | | ORR (%) | 83.8 | 77.1 | 91.7 | | | DCR (%) | 100 | 100 | 100 | |
|
|
